Alternative asset management firm TPG (NASDAQ: TPG) declared on Monday that it has made a strategic investment in K2 Medical Research, an integrated clinical trial site platform specialising in central nervous system trials.

Founded by CEO Sean Stanton and CMO Brandon Lenox, K2 operates clinical trial sites across Florida, focusing on complex therapeutic areas such as Alzheimer's and psychiatry. With a robust track record of over 150 studies for leading pharma sponsors, including AbbVie and Johnson & Johnson, K2 is known for its strong site operators and community-focused approach.

The partnership aims to enhance K2's capabilities in patient recruitment, utilising a diverse staffing model, and deploying a mobile research unit (Wanda) to engage local communities directly. K2's agile start-up process and fully integrated technology platform streamline clinical trial management from initiation to completion, reinforcing its leadership in clinical research.

Financial terms of the investment were not disclosed.

Foley & Lardner LLP advised K2, while Latham & Watkins LLP represented TPG, with Harris Williams serving as financial advisor to TPG.